Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/imm.12715 http://scihub22266oqcxt.onion/10.1111/imm.12715 C5461105!5461105!28108989     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Immunology 2017 ; 151 (3): 280-90 Nephropedia Template TP {{tp|p=28108989|t=2017. TIGIT signalling pathway negatively regulates CD4+ T?cell responses in systemic lupus erythematosus |pdf=|usr=}}{{28108989}} gab.com Text TIGIT signalling pathway negatively regulates CD4+ T cell responses in systemic lupus erythematosus JO: Immunology http://www.kidney.de/pget.php?&tw=1&pmid=28108989 #FOAvip B?lymphocyte hyperactivity in systemic lupus erythematosus (SLE) is T?cell?dependent, and CD4+ T?cell activation is essential to SLE pathogenesis. However, the mechanism of the deregulation of CD4+ T cells in SLE is largely unknown. T?cell immunoglobulin and ITIM domain (TIGIT) is a new inhibitory receptor preferentially expressed on activated CD4+ T cells. Here, we address the role of TIGIT in the pathogenesis of SLE. Our results showed that TIGIT expression on CD4+ T cells was significantly elevated in patients with SLE and highly correlated with the activity of the disease. TIGIT+CD4+ T cells from both healthy individuals and patients with SLE had a more activated phenotype than TIGIT?CD4+ T cells. In contrast, the activation, proliferation and cytokine production potential of TIGIT+CD4+ T cells were significantly lower than those of TIGIT?CD4+ T cells. Furthermore, activation of the TIGIT pathway by using CD155 could substantially down?regulate the activities of CD4+ T cells from SLE patients in vitro, and in vivo administration of CD155 resulted in a delayed development of SLE in MRL/lpr mice. TIGIT is a powerful negative regulator of CD4+ T cells in SLE, which suggests that the TIGIT signalling pathway may be used as a potential therapeutic target for treating this disease. Twit Text FOAVip TIGIT signalling pathway negatively regulates CD4+ T cell responses in systemic lupus erythematosus ????Immunology http://www.kidney.de/pget.php?&tw=1&pmid=28108989 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28108989 #FOAvip English Wikipedia <ref>{{Cite pmid|28108989}}</ref> TIGIT signalling pathway negatively regulates CD4+ T?cell responses in systemic lupus erythematosus #MMPMID28108989 Mao L; Hou H; Wu S; Zhou Y; Wang J; Yu J; Wu X; Lu Y; Mao L; Bosco MJ; Wang F; Sun Z Immunology 2017[Jul]; 151 (3): 280-90 PMID28108989show ga B?lymphocyte hyperactivity in systemic lupus erythematosus (SLE) is T?cell?dependent, and CD4+ T?cell activation is essential to SLE pathogenesis. However, the mechanism of the deregulation of CD4+ T cells in SLE is largely unknown. T?cell immunoglobulin and ITIM domain (TIGIT) is a new inhibitory receptor preferentially expressed on activated CD4+ T cells. Here, we address the role of TIGIT in the pathogenesis of SLE. Our results showed that TIGIT expression on CD4+ T cells was significantly elevated in patients with SLE and highly correlated with the activity of the disease. TIGIT+CD4+ T cells from both healthy individuals and patients with SLE had a more activated phenotype than TIGIT?CD4+ T cells. In contrast, the activation, proliferation and cytokine production potential of TIGIT+CD4+ T cells were significantly lower than those of TIGIT?CD4+ T cells. Furthermore, activation of the TIGIT pathway by using CD155 could substantially down?regulate the activities of CD4+ T cells from SLE patients in vitro, and in vivo administration of CD155 resulted in a delayed development of SLE in MRL/lpr mice. TIGIT is a powerful negative regulator of CD4+ T cells in SLE, which suggests that the TIGIT signalling pathway may be used as a potential therapeutic target for treating this disease. äTIGIT signalling pathway negatively regulates CD4+ T?cell responses in(epmc).pdf DeepDyve Pubget Overpricing